Gene delivery to dendritic cells ( DCs ) could represent a powerful method of inducing potent, long -lasting immunity. Although recent studies underline the intense interest in lentiviral vector -mediated monocyte -derived DC transduction, efficient gene transfer methods currently require high multiplicities of infection and are not compatible with clinical constraints. We have designed a strategy to optimize the efficiency and clinical relevance of this approach. Initially, using a third generation lentiviral vector expressing green fluorescent protein, we found that modifying the vector design, the DC precursor cell type, and the DC differentiation stage for transduction results in sustained transgene expression in 75 -85% of immature DCs ( transduction at a multiplicity of infection of 8 ). This high efficiency was reproducible among different donors irrespective of whether DCs were expanded from fresh or cryopreserved CD14 + precursors. We then developed procedures that bypass the need for highly concentrated lentiviral preparations and the addition of polybrene to achieve efficient transduction. DCs transduced under these conditions retain their immature phenotype and immunostimulatory potential in both autologous and allogeneic settings. Furthermore, genetically modified DCs maintain their ability to respond to maturation signals and secrete bioactive IL -12, indicating that they are fully functional. Finally, the level of transgene expression is preserved in the therapeutically relevant mature DCs, demonstrating that there is neither promoter -silencing nor loss of transduced cells during maturation. The novel approach described should advance lentiviral -mediated monocyte -derived DC transduction towards a clinical reality.
A ntigen presentation is a critical element for the induction of efficient cellular immune responses. In this respect, dendritic cells (DCs ) are now being widely investigated as immunotherapeutic vehicles for the treatment of a variety of pathologies. Properties of DCs include the ability to capture, process, and present foreign antigens, migrate to lymphoid -rich tissues, and stimulate cellular antigen-specific immune responses. 1, 2 This functional profile suggests that, under certain conditions, DCs may represent an ideal tool for the immunotherapy of cancer. 3, 4 The ability to study DCs has been dramatically improved with the development of culture systems that permitted their ex vivo expansion from either rare CD34 + progenitors or more abundant peripheral blood monocytes. 5 The development of methods to generate large numbers of DCs by the culture of circulating monocytes in the presence of interleukin -4 ( IL -4 ) and granulocyte -macrophage colonystimulating factor (GM -CSF ) for 7 days 6 makes these cells a common and convenient source for in vitro studies of DCs and evaluation of their potential use in a clinical setting upon loading with antigens of interest. In vivo, DCs scavenge antigens in tissues and, upon inflammatory stimuli, present peptides derived from these antigens to T cells. 2 Although little is known about the exact mechanisms by which DCs modulate immunity, it is obvious that one of the important parameters in determining the efficacy of DC -based immunotherapy is the control of antigen loading of DCs. Approaches in which DCs were pulsed by incubation with purified proteins, cell lysates, and synthetic peptides have shown promise, although the persistence of antigens on these pulsed DCs is relatively short. 2,7 -9 Alternatively, genetic approaches to antigen loading, based on physical or viralbased transfer of DNA or RNA encoding specific antigens, offers the advantage of a continuous supply of antigen for presentation and a broader spectrum of MHC peptide epitopes presented by DCs.
DCs are susceptible to a variety of gene transfer methods, which can be used to express either defined antigens or immunostimulatory cytokines to enhance specific immune responses. 10, 11 In this respect, several viral vector -based transduction strategies have been evaluated for gene delivery into DCs either through transduction of CD34 + cells or peripheral blood monocytes as DC precursors, or by direct transfer into differentiated DCs. Retroviral vectors derived from Murine Leukemia Virus (MLV ) have been successfully used to transduce CD34 + progenitors present in hematopoietic progenitor -rich tissues, 12 -14 but these vectors require dividing cells for efficient integration and expression. 15 Although interesting clinical data have been raised with CD34
+ progenitors, 16 monocyte -derived DCs have emerged as a common and convenient source of DCs for clinical use. These cells, however, are not dividing and thus not susceptible to MLV -mediated gene transfer. Adenovirusmediated monocyte -derived DC transduction has been utilized, but efficient gene transfer requires a high virus doses and is accompanied by the coexpression of viral proteins. 17 -19 Among the retroviral vectors, lentiviruses offer the unique opportunity to investigate genetically modified monocyte -derived DCs because they do not require cell division for efficient and stable integration into the host cell genome, and do not express viral proteins. 20, 21 Human immunodeficiency virus -1 ( HIV -1) -based vectors, pseudotyped with vesicular stomatitis virus G proteins ( VSV -G ), have been recently reported to transduce monocyte -derived DCs without impairing their biological activity, including their capacity to induce antigen -specific cytotoxic T lymphocyte (CTL ) responses, a critical issue for cancer immunotherapy. 22 -26 Although these studies clearly demonstrated the feasibility of lentiviral -mediated DC transduction, they currently required high multiplicities of infection ( MOI ) and were poorly compatible with clinical constraints. In this study, using a vector expressing green fluorescent protein (GFP ), we describe safe and efficient strategies to optimize lentivirus -mediated monocytederived DC transduction and discuss their implications for clinical applications.
Materials and methods

Lentiviral vectors
RRLTpgkGFPsin18 is a third generation lentiviral vector that was modified by inserting a 180 -bp fragment from pCMVÁR8.91 encompassing the cPPT and the CTS of HIV -1 27, 28 in central position and sense orientation in the RRLpgkGFPsin18 vector. 29 The 180 -bp fragment was amplified by polymerase chain reaction using the following primers, 5 0 CGA TCT CGA GAT GGC AGT ATT CAT CCA C and 3 0 TGA CGA ATT CTG CTG TCC CTG TAA TAA ACC, and cloned into the relevant XhoI and EcoRI sites located upstream of the human phosphoglycerate kinase ( pgk) promoter in RRLpgkGFPsin18.
Lentiviral vector production
Production of HIV -1-derived vectors expressing GFP driven by the pgk promoter and pseudotyped with the VSV -G envelope protein was achieved by cotransfecting 293 T cells with three plasmids, essentially as previously described. 21 The HIV -derived packaging construct used was pCMVÁR8.91, which encodes the HIV -1 Gag and Pol precursors as well as the regulatory proteins Tat and Rev. 30 VSV -G was expressed from pMD.G 21 and the vector plasmid was RRLTpgkGFPsin18. Briefly, 24 hours after transient transfection of 293 T cells with polyethylene imine ( PEI; Sigma, St. Louis, MO ), viral supernatants were collected, filtered through 0.45-m low protein -binding filters (Nalgene, Rochester, NY ), and concentrated as previously described. 31 The viral pellets were then resuspended in 1 /100 vol of PBS. Viral stocks were stored in aliquots at À 808C and the titers were determined by transducing HeLa T cells in a limiting dilution assay. Lentiviral vector preparations collected 24 hours posttransfection displayed titers of 10 8 -10 9 transducing units (TU )/ mL in HeLa T cells. No replication -competent virus was detected in the concentrated lentiviral stocks. A second production cycle was repeated after 24 hours, routinely generating lentiviral vector preparations of approximately 5Â10 7 -5Â10 8 TU /mL.
Generation of DCs from PBMCs and lentiviral transduction
Peripheral blood was obtained from normal donors and PBMCs were isolated by Ficoll density gradient centrifugation. Direct magnetic cell sorting of CD14 + monocytes from PBMCs was performed using MACS CD14 + microbeads ( Miltenyi Biotec Gmbh, Germany ) according to the manufacturer. CD14 + cells were then either directly used for DC differentiation or cryopreserved for future cultures. Purified CD14 + monocytes were plated at a density of 10 5 cells /well in 12 -well tissue culture plates in 1 mL of RPMI 1640 supplemented with 10% AB serum, 2 mM L -glutamine, 100 U /mL penicillin, 100 g /mL streptomycin ( BioWhittaker Europe, Verviers, Belgium ), in the presence of 800 U /mL GM -CSF and 1000 U /mL IL -4 ( both a kind gift of Schering -Plough, Kenilworth, NJ ). Cultures were fed every other day with fresh medium containing GM -CSF and IL -4 for 7 days. At day 7, most of the nonadherent cells were immature DCs, showing little or no expression of CD83 and a typical DC morphology by microscopic examination.
Twenty-four hours after monocyte isolation, cells were exposed for 24 hours to lentivirus vector preparations with MOI ranging from 2 to 20, in a volume of 500 L in the presence of 4 g/mL polybrene (Sigma), unless otherwise stated. Cells were then washed, cultured for six additional days, and analyzed for GFP expression by FACS analysis.
Cryopreservation and recovery of CD14 + monocytes
Purified CD14 + cells were resuspended at a density of 20-40Â10 6 cells/mL in RPMI medium containing 50% decomplemented human AB serum (BioWhittaker ) and kept on wet ice. Then, an equal volume of cold RPMI medium containing 50% decomplemented AB serum and 20% dimethylsulfoxide (DMSO, Merck, Darmstadt, Germany ) was added dropwise. The resulting suspension was dispensed in cold cryogenic storage vials, and placed for 24 hours at À 808C in a freezing container (Nalgene 5100 Cryo 18C Freezing container ) before transfer to vapor phase liquid nitrogen. For recovery, the cryopreserved cells were rapidly thawed in a 378C water bath, transferred into a centrifuge tube, and washed twice with RPMI medium containing 10% decomplemented AB serum to eliminate DMSO. Cells were counted 6 hours after thawing using
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DC maturation and IL -12 secretion
Untransduced and lentiviral vector -transduced DCs were plated 7 days following monocyte isolation at 10 5 cells / mL and further incubated for 40 hours in RPMI, 2% autologous serum, 800 U /mL GM -CSF, and 1000 U /mL IL -4 supplemented or not with polyriboinosinic -polyribocytidylic acid (poly( I:C ), 30 g/mL; Sigma). DCs were analyzed for the presence of maturation -specific cell surface markers by flow cytometry and culture supernatants were analyzed for the secretion of IL -12 p70 (bioactive heterodimer ) by ELISA (Endogen Human IL -12 p70 ELISA kit ) according to the manufacturer.
Flow cytometry analysis
Phenotypic staining and GFP expression of lentiviral vector -transduced and control DCs were analyzed 7 days postmonocyte isolation, thus 6 days posttransduction. Phycoerythrin (PE ) -conjugated monoclonal antibodies recognizing the following surface markers were used: CD14, CD80, CD83, CD86 (all from Becton Dickinson, San Jose, CA ), HLA DR (Serotec, Oxford, UK ), and CD40 ( Immunotech, Marseille, France ). Isotype controls ( Probio, Margate Kent, UK ) were run in parallel. Analysis was carried out with an Epics XL MCL (Coulter, Marseille, France ) flow cytometer after acquisition of 5000 -10,000 gated events.
Allogeneic and autologous mixed leukocyte reactions ( MLRs )
The ability of control and transduced DCs to induce T -cell proliferation was assessed by a standard MLR and a colorimetric immunoassay based on BrdU incorporation ( Cell Proliferation ELISA, BrdU; Boehringer -Mannheim, Germany ).
Allogeneic CD8 + T lymphocytes from normal donors were purified using a StemSep negative selection column ( purity >93% ). Briefly, 10 5 T cells were mixed with serial dilutions of control or transduced, irradiated ( 15 Gy ) DCs in 96 -well flat -bottom tissue culture plates and incubated in RPMI supplemented with 10% autologous serum for 4 days. The cultures were then pulsed with BrdU for 16 hours. BrdU incorporation into DNA was quantitated by ELISA according to the manufacturer. Results were corrected for incorporation by irradiated DCs and T cells alone. For autologous antigen-specific proliferation assays, DCs were loaded with tetanus toxoid (TT ) protein by incubation for 2 hours ( 50 g/ mL), washed twice, and used in MLR with 10 5 autologous purified CD4 + lymphocytes (StemSep negative selection column, purity >95% ).
Results
Efficient gene transfer in monocyte -derived immature DCs exposed to lentiviral vectors containing the HIV -1 central DNA flap 24 hours after isolation of CD14 + monocyte precursors
We were first interested in evaluating the transduction of immature DCs generated from CD14 + cells 24 hours after their isolation, using concentrated lentiviral vectors carrying GFP driven by the pgk promoter and containing the HIV -1 central DNA flap. So far, the adherent fractions of PBMCs have been used as DC precursors for subsequent transduction, and these monocytes were allowed to differentiate for at least 3 -8 days in the presence of IL -4 and GM -CSF before lentiviral vector exposure. We reasoned that a more appropriate and clinically compatible protocol might be to expose DC cultures to vector transduction as early as possible after the initiation of DC differentiation with IL -4 and GM -CSF to minimize the time of cell culture and allow DCs at various stages of differentiation to be compared for their ability to present antigen. We thus performed transduction assays at an earlier time point, 24 hours post -CD14 + monocyte isolation, based on a recent study showing DCs to be equally susceptible to gene transfer by HIV vectors on days 1, 4, and 7 postisolation, whereas freshly isolated monocytes were refractory to transduction. 32 In an attempt to optimize efficiency, we inserted the HIV -1 central DNA flap sequence into the RRLpgkGFPsin18 lentivirus vector. 29 This sequence has been reported to act as a cis -active determinant of HIV -1 genome nuclear import and has been shown to dramatically increase gene transduction efficiency in a variety of nondividing cells including primary T cells, CD34 + cells, macrophages, and neural cells. 28,33 -35 Following a single 24 -hour exposure to increasing quantities of concentrated lentiviral particles in the presence of 4 g/mL polybrene, IL -4, and GM -CSF, we consistently found transduction efficiencies ranging from approximately 12% at an MOI of 2 to greater than 80% at an MOI of 8 in monocyte -derived DCs from a normal donor. The gene transfer levels were assessed by evaluating the percentage of GFP + cells on day 6 posttransduction ( Fig 1A ) . Although the percentage of GFP + cells increased as a function of the MOI, transduction efficiencies were not affected at higher MOI, suggesting that the majority of cells were positive. Furthermore, we consistently found that dilution of the lentiviral supernatant at constant MOI did significantly reduce the performance of the vector. A representative experiment is shown in Figure 1B . The gene transfer efficiency decreased from 41% to 14% following a 2 -fold dilution of the supernatant (transduction volumes of 500 L and 1 mL, respectively ), indicating that the transduction of monocyte -derived DCs is a direct function of the lentiviral vector concentration. It is also important to underline that the reported percentages of GFP + cells represent transduction, and not pseudotransduction or transient expression from unintegrated vector forms, because both the percentage of GFP + cells and the fluorescence intensity remained stable throughout a 28-day culture period (data not shown). We found, moreover, that both the control and the transduced DCs were characterized by similar forward (FS ) and side scatter (SS ) properties upon differentiation, suggesting that the lentiviral vector did not significantly affect DC morphology and viability ( Fig 1C ) . The presence of polybrene was critical for efficient transduction (data not shown). All subsequent experiments were performed in the presence of polybrene at a concentration of 4 g /mL, unless otherwise stated.
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Reproducibility among individuals and impact of cryopreservation of recipient monocytes on lentiviral vector -mediated transduction efficiency
It may be of interest to cryopreserve large amounts of monocytes from the same donor to serve as a homogenous source of DC progenitors available for subsequent transduction. In this respect, the utilization of purified CD14 + cells as DC precursors, compared to the adherent fraction of PBMCs, might greatly facilitate the cryopreservation of target monocytes for future gene transfer. Therefore, we compared transduction efficiencies obtained following a 24-hour lentiviral vector exposure of either freshly isolated CD14 + cells or monocytes that had been cryopreserved for 1 month after CD14 + selection, as described in Materials and methods. We also investigated whether there may be differences between individuals in the susceptibility of their monocytes to lentiviral vector transduction. As shown in Figure 2 , consistently high efficient gene transfer was achieved in both fresh and cryorecovered DCs from four normal donors, thus supporting the conclusion that the method was reproducible among individuals and that cryopreservation of CD14 + cells prior to DC differentiation did not significantly affect the lentiviral vector -mediated transduction efficiency. Of note, similar results were obtained with CD14 + monocytes that had been stored for prolonged periods, up to 42 months, and the viability of DCs derived from cryopreserved CD14 + cells was not affected compared to DCs differentiated from freshly isolated cells ( data not shown ).
Factors that enhance transduction efficiency with low concentration viral supernatants: optimizing transduction parameters for low -titer viral vector stocks Using standard transduction conditions, as much as 80% of DCs was found to be transduced with a lentiviral vector supernatant titrated at 2Â10 8 TU /mL utilized at an MOI of 8. This high efficiency was achieved under optimal experimental conditions employing concentrated lentiviral vector stocks, which were readily generated with the RRLTpgkGFPsin18 vector. Lentiviral vectors for therapeutic applications, however, may fail to meet the requirements for the production of highly concentrated viral preparations either due to the size of the transgene or the presence of sequences that contribute to low viral vector production yield. Furthermore, in the case of MLV -derived retroviral vectors, the percentage of transduced cells was shown to be governed predominantly by virus concentration, 36 and we confirmed that this was also a critical parameter for lentiviral transduction of immature DCs, as illustrated in Figure 1B . The availability of highly concentrated virus preparations may thus be a limiting factor in achieving efficient transduction into DCs. Therefore, we sought to improve our initial transduction procedure and investigated whether modifications including co -centrifugation of recipient cells with lentiviral supernatant and multiple exposure to the lentiviral vector, individually and together, may enhance DC transduction, especially when low concentration lentiviral preparations were available. We first evaluated the effect of low -speed centrifugation to enhance lentiviral -mediated gene transduction by submitting DC cultures to centrifugation at 328C for 90 minutes at 800Âg simultaneously to 
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Optimized lentiviral-mediated DC transduction R Rouas et al lentiviral vector exposure. We then analyzed the percentage of GFP + cells compared to DCs that had been centrifuged prior to exposure to the same concentrated virus preparation (2Â10 8 TU /mL ). In the experiment illustrated in Figure 3A , transduction efficiencies were significantly increased from 36% to 58% at an MOI of 4, and from 54% to 86% at an MOI of 6. Centrifugation did not significantly enhance the transduction efficiency at an MOI of 8 and higher, suggesting that in these conditions, the majority of cells were transduced in the absence of centrifugation. We then examined whether centrifugation may be relevant with low viral vector doses that were shown to be inefficient in the standard protocol. Therefore, we evaluated the transduction efficiency with a lentiviral vector preparation titrated at 4Â10 7 TU / mL. Remarkably, transduction was rescued using low-speed co -centrifugation of DCs with the lentiviral supernatant used at low MOI. As shown in Figure 3B , at an MOI of 2, as much as 41% of the co -centrifuged DCs was GFP + , whereas cells that were centrifuged prior to lentiviral exposure did not exhibit significant differences in GFP expression compared to control untransduced DCs. Centrifugally transduced DCs were, furthermore, not damaged and behaved similarly in subsequent cultures. Taken together, these data indicate that the co-centrifugation of lentiviral supernatant with 24 -hour DC cultures partially overcomes the limitation caused by low virus stock availability.
Co -centrifugation of DCs and lentiviral vector bypasses the need for polybrene to achieve high transduction efficiency
In the absence of polybrene, monocyte -derived DC cultures exposed to the lentiviral vector 24 hours after monocyte isolation were refractory to transduction by the standard procedure, irrespective of the viral vector concentration. Co -centrifugation of lentiviral vector with recipient DCs bypasses the need for polybrene to achieve efficient transduction. DCs were generated, cultured, and treated as described in the legend of Figure 3 except that transduction was carried out in the absence of polybrene. DCs were exposed to MOI of 5, 10, and 20 of a lentiviral supernatant titrated at 2Â10 8 TU / mL. Empty and filled histograms represent noncentrifugally and centrifugally transduced DCs, respectively. The percentage of GFP + cells is indicated for the co -centrifuged condition. Figure 5 Multiple exposure to lentiviral vector provides an additional gain in DC transduction efficiency. DCs were generated and cultured as described in Figure 1 , exposed to lentiviral supernatant 24 hours postmonocyte isolation, and further differentiated ( empty histograms ) or treated by a second lentiviral vector exposure 24 hours after the first transduction ( filled histograms ) and analyzed for GFP expression 7 days after isolation. A: Both the transductions were carried out in the absence of centrifugation at an MOI of 6 of a lentiviral vector supernatant titrated at 2Â10 8 TU / mL. B: DCs were first exposed to an MOI of 2 of a lentiviral supernatant titrated at 4Â10 7 TU / mL in the absence of centrifugation followed by a centrifugation -aided transduction with the same supernatant. C: DCs were submitted to two subsequent co -centrifugations at 24 -hour interval with a an MOI of 10 of the lentiviral vector supernatant titrated at 2Â10 8 TU / mL, in the absence of polybrene. Percentages representing GFP + cells following single and double exposures to the vectors are indicated.
Increasing the MOI to 20 did not result in increased transduction above 5%. When co-centrifugation was carried out, however, the DC cultures became susceptible to transduction in the absence of polybrene. Figure 4 shows that 28% and 67% of cells within the transduced DC cultures were GFP + 7 days posttransduction, with concentrated lentiviral vector supernatants used at MOI of 5 and 10, respectively. At an MOI of 20, over 80% of transduction was achieved. Similar levels of GFP expression were found 3 weeks after exposure, indicating that the observed percentages did not result from pseudotransduction (data not shown). We have thus established conditions for lentiviral vectors to support gene transfer in monocytederived DC in the absence of polybrene.
Multiple exposure to lentiviral vector provides an additional gain in transduction efficiency
Co -centrifugation of target cells with the lentiviral vector supernatant increased gene transfer and bypassed the need for polybrene to achieve efficient DC transduction. To assess whether multiple exposure to the lentiviral vector had any effect on the transduction efficiency, we examined the impact of a second transduction on the level of GFP + cells. DCs treated with an additional exposure to the lentiviral vector showed a substantial increase in transduction efficiency. Figure 5 illustrates the impact in three independent experiments. First, two transductions at 24 -hour interval in the presence of polybrene led to over 85% GFP + cells vs 68% for a single exposure to concentrated lentiviral vector supernatant (Fig 5A ) . Most notably, when superinfection was combined with co-centrifugation of DCs, using a poorly efficient vector preparation that induced only a low number of GFP + cells following a single exposure in the absence of centrifugation, the efficiency reached as much as 85% ( Fig 5B ) . In addition, there was also an increase in the mean fluorescence intensity of GFP + cells. We finally examined whether the efficiency was enhanced when transduction was carried out in the absence of polybrene. As shown in Figure 5C , transduction efficiencies were as great as 80% following a double co -centrifugation of DCs with lentiviral vector supernatant, whereas only 58% of DCs was GFP + upon a single exposure in the absence of polybrene. This indicates that multiple exposure of DCs to lentiviral vectors is efficient in enhancing the level of gene transfer and provides an additional gain in transduction efficiency when employed in combination with co -centrifugation in the presence or absence of polybrene.
DCs transduced with optimized procedures retain their immature DC phenotype, and preserve their maturation capacity and immunostimulatory function
Although previous studies have shown lentiviral vectortransduced DCs to be fully functional, 22 -26 it remained to be verified whether there was any impact of the procedures used in this study on DC function. We first analyzed the expression of DC -associated surface markers by flow cytometry 6 days posttransduction, thus 7 days after initiation of DC differentiation. As shown in Table 1 , the expression patterns of the selected phenotypic markers were not affected in transduced DCs exhibiting 75% GFP + cells compared to untransduced populations. When compared Immature DCs were transduced as described in the legend to Figure 5B and subsequently analyzed for the expression of phenotypic markers and GFP by flow cytometry, 7 days postmonocyte isolation ( immature DCs ). Half of the cultures was then treated with poly( I:C ) for 48 hours prior to analysis ( mature DCs ). Represented are the percentages of positive cells for each marker, followed by the MFI between parentheses, compared to the corresponding isotype controls. One representative experiment of two experiments is shown. 
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Optimized lentiviral-mediated DC transduction R Rouas et al with isotype control, the majority of cells cultured for 7 days with GM -CSF and IL -4 stained strongly positive for HLA -DR, CD86, and CD40, at lesser relative intensities for CD80, and negative for CD83 and the monocyte marker CD14, in both transduced and control cell populations. Both the GFP + and GFP À cells expressed these markers at similar levels. It is important to note that transduction in itself did not induce expression of CD83, a mature DC marker, 37 suggesting that neither the lentiviral vector nor the transduction procedures did induce DC maturation.
We then evaluated the response of transduced DCs to maturation signals. Induction of these immature DCs to differentiate into mature DCs in the presence of poly( I:C ) 38, 39 was accompanied by a clear increase in CD83 expression and, to a lesser extent, in HLA -DR, CD86, and CD80 in all examined cell populations, demonstrating that transduced DCs maintained their ability to respond to activation signals such as double -stranded RNA. In addition, the percentage of GFP + cells observed in immature DCs was maintained upon maturation, with a slight but reproducible increase of the MFI, suggesting that the level of transgene expression was conserved in mature transduced DCs. Similar results were obtained with DCs transduced in the absence of polybrene ( data not shown ). We then investigated whether mature DCs secreted bioactive IL -12 p70, a key cytokine for CTL responses. 40, 41 We found that transduced DCs produced equivalent levels of this cytokine, suggesting that the genetically modified mature DCs were not altered in their capacity to respond to maturation stimuli ( Fig 6) . Altogether, our data show that there was no impact of the transduction procedures on DC immunophenotype and that transduced immature DCs were susceptible to maturation signals without concomitant loss of transgene expression.
We then tested whether transduced DCs were equally competent at eliciting an allogeneic CD8 + T -cell response in MLR. Transduction of immature DCs 24 hours postmonocyte isolation did not alter their capacity to stimulate alloreactive T -cell proliferation, suggesting similar antigen-presenting functions of untransduced and lentivirally transduced DCs ( Fig 7A ) . Finally, we examined the ability of genetically modified DCs to take up, process, and present foreign antigen to autologous CD4 + T cells. We found that transduced and untransduced DCs, loaded with TT and used as antigen -presenting cells in an autologous CD4 + T -cell proliferation assay, showed similar immunostimulatory potential ( Fig 7B ) . Thus, our data provide evidence that lentivirus -mediated transduction of immature DCs did not perturb their functional capacity. In conclusion, the phenotypic analyses and functional assays indicated that monocyte -derived lentiviral vector -transduced DCs were as equivalent to nontransduced DCs.
Discussion
This study describes the lentiviral -mediated transduction of monocyte -derived DCs in an experimental setting designed to increase gene transfer efficiency and compatibility with clinical constraints. Our results indicate that highly efficient transduction can be achieved with both high -and low -titer GFP -expressing lentiviral vector stocks following modifications of previously described techniques, including (a ) the insertion of the central DNA flap sequence in the vector construct; ( b) the utilization of purified CD14 + cells as DC precursors; and ( c) the exposure of recipient cells to the lentiviral vector 24 hours postmonocyte isolation. Our work, furthermore, demonstrated that the efficiency achieved in these conditions was reproducible among individuals irrespective of whether fresh or cryorecovered CD14 + monocytes were employed for transduction. We also analyzed the impact of technical modifications designed to fit with a clinical setting in which either limiting amounts of lentiviral vector or poorly efficient virus preparations might be available. We found that co -centrifugation and multiple exposure to the vector resulted in efficient and sustained gene transfer with lentiviral preparations that were previously inefficient, and demonstrated the feasibility of high -level 
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Gene delivery to DCs could represent a powerful method of inducing potent, long -lasting immunity. Although several studies demonstrated the feasibility of VSV -G pseudotyped lentiviral -mediated monocyte -derived DC transduction, 22 -24,26 efficient gene transfer protocols required high MOI and were poorly compatible with therapeutic limitations. The combination of a convenient ex vivo DC expansion method from blood precursors and the possibility to use lentiviral vectors to transduce these DCs provided, nevertheless, rationale to further optimize this approach in terms of efficiency and clinical relevance.
The predicted efficiency of lentiviral vector -mediated DC transduction depends, in part, on the vector design and production method. An additional major determinant, however, is the permissiveness of the target cell, a factor which is affected by both the selection strategy utilized for monocyte isolation and the differentiation stage of the cell at the time of lentiviral vector exposure. Our first strategy to improve monocyte -derived DC transduction was to insert the central DNA flap sequence into the RRLpgkGFPsin18 vector to promote nuclear import 28,33 -35 and utilize highly concentrated lentiviral vector preparations. Furthermore, a purified CD14 + monocyte population was used preferentially as a source of DC precursors. Although this option was clearly found to be more labor -and cost -intensive compared to the utilization of the adherent fraction of PBMCs, it offered the advantage to initiate DC differentiation from a homogenous cell population. Another consequence is the possibility to accurately evaluate the number of potential target cells for transduction and the MOI, two parameters which can have profound implications on gene transfer efficiency. Most importantly, this strategy provides the opportunity to routinely store large quantities of CD14 + monocytes from the same donor in liquid nitrogen for prolonged periods (our study included samples stored for up to 42 months) with excellent postthaw viability. As effective DC -based vaccination may possibly require several immunizations as well as consolidation vaccine therapy, 3 it may be desirable in a clinical setting to cryopreserve target monocytes for future use. Another important modification in the gene transfer method was the transduction of cells 24 hours postmonocyte isolation. In contrast to previous studies, this rapid protocol offers the advantage of minimizing the time of cell culture and allows time for additional manipulations such as multiple rounds of infection prior to DC maturation. Under these conditions, the MOI of 8 used to consistently achieve over 80% of transduction in immature DCs is significantly lower than the MOI described in previous studies, where it ranged from 20 to 100 for the same efficiency, whereas most efficiencies were not greater than 40% with MOI ranging from 5 to 100. 22 -24,26,32 Furthermore, the herein demonstrated ability to reproducibly achieve high levels of gene transfer at low MOI in monocyte -derived DCs from different donors, and the feasibility to obtain similar levels in DCs derived from cryorecovered CD14 + cells from the same donor are highly desirable for DC -based vaccination. It has to be noted, however, that the differences in MOI may be difficult to interpret because different authors define virus titers on different cell types, which are more or less sensitive to transduction. The MOI, furthermore, is not an accurate predictor of the efficiency of infection because virus concentration, and not the total number of viral particles, determines infectivity. 36 We demonstrated that this was also a critical parameter for transduction of immature DCs in experiments where we compared the level of gene transfer with a vector preparation utilized at a same MOI but at different concentrations.
Whereas the gene transfer levels were very encouraging with highly concentrated RRLTpgkGFPsin18 lentiviral vector preparations, they nonetheless precluded the efficient transduction with low -titer lentiviral stocks. The availability of highly concentrated virus preparations may thus be a limiting factor in achieving efficient transduction of DCs. It is increasingly apparent, however, that lentiviral vectors for therapeutic applications may fail to generate the highly concentrated viral stocks required in a clinical setting, either due to the size of the transgene or particularities inherent to the sequence, which affect the yield of lentiviral production. Assuming that viruses with a genome of 11 kb of RNA can maintain a full infectivity, 42 the RRLTpgksin18 vector in its current configuration should be able to accommodate transgenes of approximately 8.6 kb. 29 However, we did not confirm this speculation, but rather found that large inserts greatly affected the RRLTpgksin18 -mediated transduction efficacy (unpublished observations ). Whereas low efficiency gene transfer can be overcome by sorting of the genetically modified cells, based on either the surface expression of the transgene itself or the coexpression of a selectable marker such as GFP, immune responses to these markers may interfere with its applicability in immunotherapy protocols. In this respect, the use of single -gene vectors is a prerequisite for clinical trials, as it may minimize competition between transgene and marker gene peptides for MHC presentation and further diminish elimination of transduced DC by marker -specific cytolytic cells. 43 Thus, therapeutic vectors might not be ideal both in terms of efficiency and ease of detection. We showed here that both co-centrifugation of the lentiviral vector with the DCs and multiple exposures to the vector resulted in a significant improvement in gene transfer mediated by low -titer virus stocks, with efficiencies reaching as much as 85%. Using highly concentrated lentiviruses, however, we found that the same conditions did not increase the fraction of transduced cells when using MOI above 6, suggesting that either a fraction of DCs is refractory to lentiviral vector -mediated transduction or that all cells were transduced with the standard protocol. At lower MOI, however, there was a substantial reduction of the number of viral vector particles needed for a similar gene transfer level. Most notably, cocentrifugation bypassed the need for polybrene to achieve efficient transduction with as much as 80% of GFP + cells at an MOI of 20 and an additional gain when co-centrifugation was combined with a second exposure to the virus (an MOI of 10 to achieve 80% efficiency ). The ability to obtain satisfying gene transfer efficiencies in the absence of membrane agents such as polybrene, although restricted to high -titer virus stocks, should contribute to the development of clinically acceptable strategies for the genetic modification of monocyte -derived DCs.
The clinical relevance of using a lentiviral vector in monocyte -derived DCs will be dependent on the ability of transduced DCs to generate a robust therapeutic or protective immune response. Although previous reports have shown that lentiviral -transduced DCs were equivalent to control DCs in eliciting T -cell responses, it remained to be determined whether the experimental conditions used in our study may alter DC function. First, we found that DCs transduced with the DNA flap -modified lentiviral vector and optimized procedures retain their immature phenotype, in contrast to adenovirus -mediated gene transfer that, in itself, induces DC maturation. 44 This finding may be beneficial for achieving high -level gene transfer through successive lentiviral exposures, as it has been shown that mature DCs display a marked decrease in their ability to support efficient transduction. 24, 32 Most importantly, we found that lentiviral -transduced DCs treated with co -centrifugation and superinfection retained their immunostimulatory potential in both autologous and allogeneic settings and conserved their capacity to respond to maturation signals. DC maturation is a critical parameter for the use of these cells in active immunization of patients. In our study, we used exposure to the synthetic dsRNA, poly( I:C ), a clinically applicable method, to induce stable maturation of DCs. 39 Poly( I:C ) triggered effective maturation of both control and transduced DCs as demonstrated by the up -regulation of CD83 expression and the secretion of large quantities of bioactive IL -12 p70, indicating that the lentiviral vectormodified monocyte -derived DCs were fully functional. Finally, it is remarkable that the level of transgene expression was conserved in these therapeutically relevant mature DCs, with a slight but reproducible increase in the mean fluorescence intensity, suggesting that in contrast to previous observations, 45 there was neither postintegration promoter silencing nor loss of transduced cells during maturation. Both the IL -12 secretion and the high -level transgene expression associated with mature transduced DCs are critical in generating strong CTL responses. In this respect, recent work from Firat et al 46 clearly demonstrated that the inclusion of a DNA flap sequence in a melanoma polyepitope-encoding recombinant HIV -1 vector elicited vigorous and multispecific long -term antimelanoma CTL responses both in vitro and in vivo, whereas the parental vector lacking the flap sequence was less efficient. Moreover, these stronger and more reliable CTL responses, especially in vivo, were shown to be directly correlated to the enhanced transduction efficiency mediated by the modified vector. Thus, both the abundant IL -12 secretion and the high -level transgene expression observed with our mature DNA flap -modified lentiviral -transduced DCs strongly suggest that these DCs have the potential to elicit potent multiepitope-specific CTL responses directed against therapeutically relevant transgenes.
DC -based vaccination and immunotherapy are at an early stage, and several parameters for achieving safe and efficient therapeutic or protective effects need to be evaluated. Here we have addressed the control of antigen delivery, a critical issue for the genetic modification of therapeutically relevant DCs. We have established optimized conditions for lentiviral vector -mediated DC transduction that meet the prerequisites for efficient gene transfer within the boundaries of preserving the essential functions of DC.
In conclusion, the novel strategies developed here will advance lentiviral vector -mediated monocyte -derived DC transduction toward requirements of clinical applications.
